{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T13:26:20Z","timestamp":1791033980080,"version":"4.1.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2009,4,9]],"date-time":"2009-04-09T00:00:00Z","timestamp":1239235200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2009,7]]},"DOI":"10.1007\/s00228-009-0646-3","type":"journal-article","created":{"date-parts":[[2009,4,8]],"date-time":"2009-04-08T09:02:14Z","timestamp":1239181334000},"page":"651-658","source":"Crossref","is-referenced-by-count":23,"title":["The pharmacokinetics of codeine and its metabolites in Blacks with sickle cell disease"],"prefix":"10.1007","volume":"65","author":[{"given":"Stacy S.","family":"Shord","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larisa H.","family":"Cavallari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihua","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun-Young","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Deyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shitalben R.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph R.","family":"Camp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan M.","family":"Labott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert E.","family":"Molokie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,4,9]]},"reference":[{"key":"646_CR1","doi-asserted-by":"crossref","unstructured":"Aasmundstad TA, Storset P 1998 Influence of ranitidine on the morphine-3-glucuronide to morphine-6-glucuronide ratio after oral administration of morphine in humans. Hum Exp Toxicol 17:347\u2013352","DOI":"10.1191\/096032798678908837"},{"key":"646_CR2","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/00008571-200207000-00005","volume":"12","author":"E Aklillu","year":"2002","unstructured":"Aklillu E, Herrlin K, Gustafsson LL, Bertilsson L, Ingelman-Sundberg M (2002) Evidence for environmental influence on CYP2D6-catalysed debrisoquine hydroxylation as demonstrated by phenotyping and genotyping of Ethiopians living in Ethiopia or in Sweden. Pharmacogenetics 12:375\u2013383","journal-title":"Pharmacogenetics"},{"key":"646_CR3","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/S0006-2952(02)01351-5","volume":"64","author":"TE Bapiro","year":"2002","unstructured":"Bapiro TE, Hasler JA, Ridderstrom M, Masimirembwa CM (2002) The molecular and enzyme kinetic basis for the diminished activity of the cytochrome P450 2D6.17 (CYP2D6.17) variant. Potential implications for CYP2D6 phenotyping studies and the clinical use of CYP2D6 substrate drugs in some African populations. Biochem Pharmacol 64:1387\u20131398","journal-title":"Biochem Pharmacol"},{"key":"646_CR4","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/sj.tpj.6500378","volume":"6","author":"WM Cai","year":"2006","unstructured":"Cai WM, Nikoloff DM, Pan RM, de Leon J, Fanti P, Fairchild M, Koch WH, Wedlund PJ (2006) CYP2D6 genetic variation in healthy adults and psychiatric African-American subjects: implications for clinical practice and genetic testing. Pharmacogenomics J 6:343\u2013350","journal-title":"Pharmacogenomics J"},{"key":"646_CR5","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0090-9556(25)07426-4","volume":"24","author":"Y Caraco","year":"1996","unstructured":"Caraco Y, Tateishi T, Guengerich FP, Wood AJ (1996) Microsomal codeine N-demethylation: cosegregation with cytochrome P4503A4 activity. Drug Metab Dispos 24:761\u2013764","journal-title":"Drug Metab Dispos"},{"key":"646_CR6","first-page":"73","volume":"26","author":"BL Coffman","year":"1998","unstructured":"Coffman BL, King CD, Rios GR, Tephly TR (1998) The glucuronidation of opioids, other xenobiotics, and androgens by human UGT2B7Y(268) and UGT2B7H(268). Drug Metab Dispos 26:73\u201377","journal-title":"Drug Metab Dispos"},{"key":"646_CR7","first-page":"1","volume":"25","author":"BL Coffman","year":"1997","unstructured":"Coffman BL, Rios GR, King CD, Tephly TR (1997) Human UGT2B7 catalyzes morphine glucuronidation. Drug Metab Dispos 25:1\u20134","journal-title":"Drug Metab Dispos"},{"key":"646_CR8","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/BF00280101","volume":"41","author":"J Desmeules","year":"1991","unstructured":"Desmeules J, Gascon MP, Dayer P, Magistris M (1991) Impact of environmental and genetic factors on codeine analgesia. Eur J Clin Pharmacol 41:23\u201326","journal-title":"Eur J Clin Pharmacol"},{"key":"646_CR9","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1067\/mcp.2002.125783","volume":"72","author":"A Gaedigk","year":"2002","unstructured":"Gaedigk A, Bradford LD, Marcucci KA, Leeder JS (2002) Unique CYP2D6 activity distribution and genotype-phenotype discordance in black Americans. Clin Pharmacol Ther 72:76\u201389","journal-title":"Clin Pharmacol Ther"},{"key":"646_CR10","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1373\/49.6.1008","volume":"49","author":"A Gaedigk","year":"2003","unstructured":"Gaedigk A, Ryder DL, Bradford LD, Leeder JS (2003) CYP2D6 poor metabolizer status can be ruled out by a single genotyping assay for the -1584G promoter polymorphism. Clin Chem 49:1008\u20131011","journal-title":"Clin Chem"},{"key":"646_CR11","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/sj.clpt.6100406","volume":"83","author":"A Gaedigk","year":"2008","unstructured":"Gaedigk A, Simon SD, Pearce RE, Bradford LD, Kennedy MJ, Leeder JS (2008) The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin Pharmacol Ther 83:234\u2013242","journal-title":"Clin Pharmacol Ther"},{"key":"646_CR12","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/0304-3959(94)90088-4","volume":"56","author":"CR Goucke","year":"1994","unstructured":"Goucke CR, Hackett LP, Ilett KF (1994) Concentrations of morphine, morphine-6-glucuronide and morphine-3-glucuronide in serum and cerebrospinal fluid following morphine administration to patients with morphine-resistant pain. Pain 56:145\u2013149","journal-title":"Pain"},{"key":"646_CR13","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/sj.clpt.6100455","volume":"83","author":"J Kirchheiner","year":"2008","unstructured":"Kirchheiner J (2008) CYP2D6 phenotype prediction from genotype: which system is the best? Clin Pharmacol Ther 83:225\u2013227","journal-title":"Clin Pharmacol Ther"},{"key":"646_CR14","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/sj.tpj.6500406","volume":"7","author":"J Kirchheiner","year":"2007","unstructured":"Kirchheiner J, Schmidt H, Tzvetkov M, Keulen JT, Lotsch J, Roots I, Brockmoller J (2007) Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication. Pharmacogenomics J 7:257\u2013265","journal-title":"Pharmacogenomics J"},{"key":"646_CR15","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1191\/0269216303pm835oa","volume":"17","author":"P Klepstad","year":"2003","unstructured":"Klepstad P, Borchgrevink PC, Dale O, Zahlsen K, Aamo T, Fayers P, Fougner B, Kaasa S (2003) Routine drug monitoring of serum concentrations of morphine, morphine-3-glucuronide and morphine-6-glucuronide do not predict clinical observations in cancer patients. Palliat Med 17:679\u2013687","journal-title":"Palliat Med"},{"key":"646_CR16","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1097\/00008571-199812000-00010","volume":"8","author":"JB Leathart","year":"1998","unstructured":"Leathart JB, London SJ, Steward A, Adams JD, Idle JR, Daly AK (1998) CYP2D6 phenotype-genotype relationships in African-Americans and Caucasians in Los Angeles. Pharmacogenetics 8:529\u2013541","journal-title":"Pharmacogenetics"},{"key":"646_CR17","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/00008571-199204000-00006","volume":"2","author":"MS Lennard","year":"1992","unstructured":"Lennard MS, Iyun AO, Jackson PR, Tucker GT, Woods HF (1992) Evidence for a dissociation in the control of sparteine, debrisoquine and metoprolol metabolism in Nigerians. Pharmacogenetics 2:89\u201392","journal-title":"Pharmacogenetics"},{"key":"646_CR18","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/j.jpainsymman.2005.01.004","volume":"29","author":"J Lotsch","year":"2005","unstructured":"Lotsch J (2005) Opioid metabolites. J Pain Symptom Manage 29:S10\u201324","journal-title":"J Pain Symptom Manage"},{"key":"646_CR19","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S1570-0232(04)00642-7","volume":"811","author":"B Maralikova","year":"2004","unstructured":"Maralikova B, Weinmann W (2004) Confirmatory analysis for drugs of abuse in plasma and urine by high-performance liquid chromatography-tandem mass spectrometry with respect to criteria for compound identification. J Chromatogr B Analyt Technol Biomed Life Sci 811:21\u201330","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"646_CR20","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1046\/j.1365-2125.1996.00489.x","volume":"42","author":"C Masimirembwa","year":"1996","unstructured":"Masimirembwa C, Persson I, Bertilsson L, Hasler J, Ingelman-Sundberg M (1996) A novel mutant variant of the CYP2D6 gene (CYP2D6*17) common in a black African population: association with diminished debrisoquine hydroxylase activity. Br J Clin Pharmacol 42:713\u2013719","journal-title":"Br J Clin Pharmacol"},{"key":"646_CR21","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S0361-9230(97)00307-9","volume":"44","author":"CM Masimirembwa","year":"1997","unstructured":"Masimirembwa CM, Hasler JA (1997) Genetic polymorphism of drug metabolising enzymes in African populations: implications for the use of neuroleptics and antidepressants. Brain Res Bull 44:561\u2013571","journal-title":"Brain Res Bull"},{"key":"646_CR22","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S0009-9236(97)90196-X","volume":"61","author":"G Mikus","year":"1997","unstructured":"Mikus G, Trausch B, Rodewald C, Hofmann U, Richter K, Gramatte T, Eichelbaum M (1997) Effect of codeine on gastrointestinal motility in relation to CYP2D6 phenotype. Clin Pharmacol Ther 61:459\u2013466","journal-title":"Clin Pharmacol Ther"},{"key":"646_CR23","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/clpt.1990.4","volume":"47","author":"O Mortimer","year":"1990","unstructured":"Mortimer O, Persson K, Ladona MG, Spalding D, Zanger UM, Meyer UA, Rane A (1990) Polymorphic formation of morphine from codeine in poor and extensive metabolizers of dextromethorphan: relationship to the presence of immunoidentified cytochrome P-450IID1. Clin Pharmacol Ther 47:27\u201335","journal-title":"Clin Pharmacol Ther"},{"key":"646_CR24","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1002\/jms.1021","volume":"41","author":"F Musshoff","year":"2006","unstructured":"Musshoff F, Trafkowski J, Kuepper U, Madea B (2006) An automated and fully validated LC-MS\/MS procedure for the simultaneous determination of 11 opioids used in palliative care, with 5 of their metabolites. J Mass Spectrom 41:633\u2013640","journal-title":"J Mass Spectrom"},{"key":"646_CR25","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1016\/0024-3205(87)90710-7","volume":"41","author":"K Oguri","year":"1987","unstructured":"Oguri K, Yamada-Mori I, Shigezane J, Hirano T, Yoshimura H (1987) Enhanced binding of morphine and nalorphine to opioid delta receptor by glucuronate and sulfate conjugations at the 6-position. Life Sci 41:1457\u20131464","journal-title":"Life Sci"},{"key":"646_CR26","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/j.1365-2125.1992.tb04121.x","volume":"34","author":"R Osborne","year":"1992","unstructured":"Osborne R, Thompson P, Joel S, Trew D, Patel N, Slevin M (1992) The analgesic activity of morphine-6-glucuronide. Br J Clin Pharmacol 34:130\u2013138","journal-title":"Br J Clin Pharmacol"},{"key":"646_CR27","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1124\/mol.52.6.1034","volume":"52","author":"M Oscarson","year":"1997","unstructured":"Oscarson M, Hidestrand M, Johansson I, Ingelman-Sundberg M (1997) A combination of mutations in the CYP2D6*17 (CYP2D6Z) allele causes alterations in enzyme function. Mol Pharmacol 52:1034\u20131040","journal-title":"Mol Pharmacol"},{"key":"646_CR28","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1016\/0024-3205(87)90431-0","volume":"41","author":"GW Pasternak","year":"1987","unstructured":"Pasternak GW, Bodnar RJ, Clark JA, Inturrisi CE (1987) Morphine-6-glucuronide, a potent mu agonist. Life Sci 41:2845\u20132849","journal-title":"Life Sci"},{"key":"646_CR29","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1067\/mcp.2000.111934","volume":"68","author":"RT Penson","year":"2000","unstructured":"Penson RT, Joel SP, Bakhshi K, Clark SJ, Langford RM, Slevin ML (2000) Randomized placebo-controlled trial of the activity of the morphine glucuronides. Clin Pharmacol Ther 68:667\u2013676","journal-title":"Clin Pharmacol Ther"},{"key":"646_CR30","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1002\/jps.1131","volume":"90","author":"RT Penson","year":"2001","unstructured":"Penson RT, Joel SP, Clark S, Gloyne A, Slevin ML (2001) Limited phase I study of morphine-3-glucuronide. J Pharm Sci 90:1810\u20131816","journal-title":"J Pharm Sci"},{"key":"646_CR31","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1124\/dmd.107.015354","volume":"35","author":"H Shen","year":"2007","unstructured":"Shen H, He MM, Liu H, Wrighton SA, Wang L, Guo B, Li C (2007) Comparative Metabolic Capabilities and Inhibitory Profiles of CYP2D6.1, CYP2D6.10, and CYP2D6.17. Drug Metab Dispos 35:1292\u20131300","journal-title":"Drug Metab Dispos"},{"key":"646_CR32","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/BF00265920","volume":"42","author":"SH Sindrup","year":"1992","unstructured":"Sindrup SH, Arendt-Nielsen L, Brosen K, Bjerring P, Angelo HR, Eriksen B, Gram LF (1992) The effect of quinidine on the analgesic effect of codeine. Eur J Clin Pharmacol 42:587\u2013591","journal-title":"Eur J Clin Pharmacol"},{"key":"646_CR33","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1097\/00008571-200108000-00004","volume":"11","author":"YJ Wan","year":"2001","unstructured":"Wan YJ, Poland RE, Han G, Konishi T, Zheng YP, Berman N, Lin KM (2001) Analysis of the CYP2D6 gene polymorphism and enzyme activity in African-Americans in southern California. Pharmacogenetics 11:489\u2013499","journal-title":"Pharmacogenetics"},{"key":"646_CR34","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/00008571-200107000-00005","volume":"11","author":"A Wennerholm","year":"2001","unstructured":"Wennerholm A, Johansson I, Hidestrand M, Bertilsson L, Gustafsson LL, Ingelman-Sundberg M (2001) Characterization of the CYP2D6*29 allele commonly present in a black Tanzanian population causing reduced catalytic activity. Pharmacogenetics 11:417\u2013427","journal-title":"Pharmacogenetics"},{"key":"646_CR35","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1093\/bja\/aef284","volume":"89","author":"DG Williams","year":"2002","unstructured":"Williams DG, Patel A, Howard RF (2002) Pharmacogenetics of codeine metabolism in an urban population of children and its implications for analgesic reliability. Br J Anaesth 89:839\u2013845","journal-title":"Br J Anaesth"},{"key":"646_CR36","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1111\/j.1365-2125.1989.tb03555.x","volume":"28","author":"QY Yue","year":"1989","unstructured":"Yue QY, Svensson JO, Alm C, Sjoqvist F Sawe J (1989) Interindividual and interethnic differences in the demethylation and glucuronidation of codeine. Br J Clin Pharmacol 28:629\u2013637","journal-title":"Br J Clin Pharmacol"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-009-0646-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-009-0646-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-009-0646-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T22:16:11Z","timestamp":1739052971000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-009-0646-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4,9]]},"references-count":36,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2009,7]]}},"alternative-id":["646"],"URL":"https:\/\/doi.org\/10.1007\/s00228-009-0646-3","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,4,9]]}}}